NCT03818308 is a Phase 2 clinical trial of Sofosbuvir and Velpatasvir in Hepatitis C, sponsored by Hannover Medical School.

Who is sponsoring NCT03818308?

NCT03818308 is sponsored by Hannover Medical School.

What drugs are being tested in NCT03818308?

Interventions in NCT03818308: Sofosbuvir and Velpatasvir.

What condition does NCT03818308 study?

NCT03818308 studies Hepatitis C, Acute Hepatitis C.

Is NCT03818308 still recruiting?

NCT03818308 is currently completed. Last updated 6 July 2021.

Last reviewed 2021-07-06 · How we verify

NCT03818308

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Completed Phase 2 Last updated 6 July 2021

What this trial tests

Phase 2 trial testing Sofosbuvir and Velpatasvir in Hepatitis C in 20 participants. Completed in 8 June 2021.

Timeline

28 May 2019

Primary endpoint
8 June 2021

8 June 2021

Quick facts

Lead sponsor	Hannover Medical School
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	28 May 2019
Primary completion	8 June 2021
Estimated completion	8 June 2021
Sites	14 locations across Germany

Drugs / interventions tested

Sofosbuvir and Velpatasvir — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →
Acute Hepatitis C — all drugs for Acute Hepatitis C →

Sponsor

Hannover Medical School

Who can join

18 and older, any sex, with Hepatitis C or Acute Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute hepatitis C virus (HCV) infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study.
Maasoumy B, Ingiliz P, Spinner CD, Cordes C, et al · · 2023 · cited 17× · PMID 36852107 · DOI 10.1016/j.jhepr.2022.100650

Verify or expand the search:

Other trials of Sofosbuvir and Velpatasvir

Trials testing the same drug.

NCT03250910 — Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients · Phase 4 · completed

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03818308 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 6 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03818308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing